首页> 外文期刊>Biochemical Genetics >The Molecular Genetic Expression as a Novel Biomarker in the Evaluation and Monitoring of Patients With Osteosarcoma-Subtype Bone Cancer Disease
【24h】

The Molecular Genetic Expression as a Novel Biomarker in the Evaluation and Monitoring of Patients With Osteosarcoma-Subtype Bone Cancer Disease

机译:分子遗传表达作为一种新型生物标志物在评估和监测骨肉瘤 - 亚型骨癌病患者中的评估和监测

获取原文
获取原文并翻译 | 示例
           

摘要

One of the leading causes of death among patients with malignancies is represented by bone cancer. According to current studies, the leading cause of death among these patients is represented by late diagnosis, poor response to therapy, and the lack of accuracy in terms of clinical evaluation. In this regard, there have been developed a series of methods of diagnosis and evaluation, the most investigated being represented by miRNA expression. In this updated work, we want to present a series of changes in the expression of miRNAs in bone cancer. Moreover, we want to present the implications of miRNAs in targeted therapy in such patients. Studies available in scientific databases such as PubMed and Scopus were examined. The studies were searched using the keywords "miRNAs expression", "bone cancer", "genetic therapy" and "genetic biomarkers." For the evaluation and monitoring of bone cancer, the expression of miRNAs can be successfully used due to increased specificity. Using miRNAs as gene therapy can be also considered a therapeutic method of the future, mainly due to selective and targeted response of the body.
机译:恶性肿瘤患者的主要死因之一是骨癌代表。根据目前的研究,这些患者中死亡的主要原因是由晚期诊断,对治疗的良好反应,以及在临床评价方面缺乏准确性。在这方面,已经开发出一系列诊断和评估方法,最多调查的是MiRNA表达所代表。在这个更新的工作中,我们想提出一系列变化在骨癌中miRNA的表达。此外,我们希望在这些患者中展示miRNA在靶向治疗中的影响。研究了科学数据库的研究,如PubMed和Scopus。使用关键词“miRNA表达”,“骨癌”,“遗传疗法”和“遗传生物标志物进行搜索研究。对于骨癌的评估和监测,由于特异性增加,可以成功使用miRNA的表达。作为基因治疗的使用MiRNA也可以被认为是未来的治疗方法,主要是由于身体的选择性和靶向响应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号